Previous 10 | Next 10 |
REDWOOD CITY, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming 40 th Annual J.P. Morgan Healthcare Con...
Piper Sandler has upgraded Pulmonx (LUNG +6.6%) to overweight from neutral citing the company's recent stock price decline providing an attractive entry. The firm has a $45 price target (~33% upside based on yesterday's close). Analyst Jason Bednar writes new account additions continuing at t...
REDWOOD CITY, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will participate in the 33 rd Annual Piper Sandler Healthcare ...
Embargoed until 7 a.m. CT / 8 a.m. ET Wednesday, Nov. 3, 2021 ( NewMediaWire ) - November 03, 2021 - DALLAS - The American Heart Association (AHA), a global force for longer, healthier lives, will present its 2021 Population Research Prize to Tiffany M. Powell-Wiley, M.D., M.P.H., FAHA, o...
REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming virtual investor conferences. ...
Image source: The Motley Fool. Pulmonx Corporation (NASDAQ: LUNG) Q3 2021 Earnings Call Nov 02, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Pulmonx Corporation (LUNG) Q3 2021 Earnings Call Transcript
Pulmonx Corporation (LUNG) Q3 2021 Earnings Conference Call Nov 02, 2021 04:30 PM ET Company Participants Brian Johnston - Investor Relations, Gilmartin Group Glen French - President & Chief Executive Officer Derrick Sung - Chief Financial Officer Conference Call Participants Larry Biegel...
Pulmonx (NASDAQ:LUNG): Q3 GAAP EPS of -$0.28 beats by $0.09. Revenue of $13.26M (+25.0% Y/Y) beats by $0.08M. Press Release Pulmonx is maintaining its full year 2021 revenue guidance in the range of $49 to $51 million. For further details see: Pulmonx EPS beats by $0.09, beats on revenu...
REDWOOD CITY, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the third quarter ended September 30, 2021. ...
REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2021 after the close of tr...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2024 after the close of trading...
2024-06-23 01:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...